LinDo Delivers Your Products to Patients in Japan
Japan has the world's third-largest pharmaceutical country. However, due to complex regulations and unique market characteristics, it faces the challenge of "drug loss," where innovative overseas therapies do not reach Japanese patients.
Bringing Promising Medicines to Japanese Patients
Our mission is to deliver promising medicines from around the world to patients in Japan. To fulfill this mission, we possess robust capabilities.
These alliances, along with partnerships with top-tier specialists and companies such as ICCC (In-country Clinical Caretaker), enable us to manage the complete product lifecycle from development through marketing authorization, sales, and pharmacovigilance.
LinDo's Leadership Team
LinDo's leadership team members not only have extensive experience in global pharma but are also deeply knowledgeable about the Japanese pharmaceutical industry. They possess a thorough understanding of the local regulatory environment, the needs of the medical field, and market trends, enabling us to formulate and execute precise strategies for your product's success in the Japanese market.
LinDo's shareholders are an influential BPO (Business Process Outsourcing) service company that have provided marketing and sales services across various value chains for global pharma, a healthcare-specific venture capital firm and leading pharmaceutical distribution companies. LinDo has established strong relationships with shareholders along with our reliable partners. This allows us to provide seamless and efficient support for all aspects of your product's rapid and effective entry into the Japanese market.
We formulate optimized strategies for each product based on Japanese regulations, from clinical trials to regulatory applications, establishing the shortest route to approval.
We identify target hospitals and physicians, implementing efficient and effective plans that combine digital and MR activities to maximize product awareness and sales.
We explore new logistics models tailored to product characteristics, building a safe, reliable, and efficient product supply chain that fundamentally supports stable market expansion.
Interested in opportunities in Japan?
Request a Japanese Market Forecast Report to assess your product's market potential in Japan. We prepare a report tailored to your company based on non-confidential product information and discussions with your team, providing practical insights to support your market entry strategy.
Let's move your innovation forward.
LinDo pipeline at a Glance
Our mission is to deliver promising medicines from around the world to patients in Japan. To fulfill this mission, we possess robust capabilities.
As of July 15, 2026
| Generic name, Development Code | Route of Administration | Indication | Status | Status |
|---|---|---|---|---|
| Glycopyrronium bromide oral solution | Oral | Sialorrhea with chronic pediatric neurological disorders | Preparing for clinical trials | - In-licensed from Proveca - Approved in the EU and other regions |
